Bayer - Haplogen/ TargetPicV
In November 2012, Evotec and Haplogen GmbH signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Under the agreement, Haplogen and Evotec co-develop drugs against a human protein that is essential for pathogenic viruses to infect their host cell. This protein was discovered by Haplogen's powerful proprietary technology to identify host factors for infectious human pathogens. Evotec further develop Haplogen's lead compounds and apply its drug discovery platform to find additional small molecule inhibitors. Terms of the partnership were not disclosed.
In August 2018, Haplogen entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (“COPD”). Evotec and Haplogen’s target-based approach will be broadened under the terms of the new Haplogen collaboration with Bayer.
As part of the new Haplogen collaboration, Bayer receives an exclusive license to worldwide rights to programmes developed within the collaboration between Haplogen and Evotec. Evotec will participate in undisclosed upfront as well as potential milestone and royalty-based payments from Haplogen.